Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.69 |
| ▸ | HPGD | P15428 | 7/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | GLA | P06280 | 6/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 5/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.69 |
| ▸ | ACHE | P22303 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847409 | 1.00 | KDM4E (0.69) | KDM4EHPGDALDH1A1GLAHSD17B10 | |
| Hydrochloric Acid SCHEMBL2851355 | 0.99 | KDM4E (0.68) | KDM4EHPGDALDH1A1GLAHSD17B10 | |
| Hydrochloric Acid SCHEMBL1690850 | 0.99 | KDM4E (0.68) | KDM4EHPGDALDH1A1GLAHSD17B10 | |
| SCHEMBL3482463 | 0.87 | KCNH2 (0.56) | KDM4EHPGDALDH1A1GLAHSD17B10 | |
| SCHEMBL5612677 | 0.86 | KDM4E (0.67) | KDM4EHPGDALDH1A1GLAHSD17B10 | |
| SCHEMBL3482799 | 0.86 | KCNH2 (0.55) | KDM4EHPGDALDH1A1GLAHSD17B10 | |
| SCHEMBL26109570 | 0.85 | KDM4E (0.61) | KDM4EHPGDALDH1A1GLAHSD17B10 | |
| Water SCHEMBL28943973 | 0.84 | KDM4E (0.60) | KDM4EHPGDALDH1A1GLAHSD17B10 | |
| Sulfuric Acid SCHEMBL26103985 | 0.82 | KDM4E (0.57) | KDM4EHPGDALDH1A1GLAHSD17B10 | |
| Alfuzosin SCHEMBL34477 | 0.82 | KDM4E (1.00) | KDM4EHPGDALDH1A1GLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069562-A1 | Process for the preparation of alfuzosin | AUROBINDO PHARMA LTD (IN) | 2009-03-12 | — | — | US | claimed |
| WO-2007074364-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | AUROBINDO PHARMA LIMITED (IN) | 2007-07-05 | — | — | WO | claimed |
| EP-0582502-B1 | Transdermal composition containing alfuzosin | SYNTHELABO (FR) | 1998-12-02 | — | — | EP | claimed |
| US-5523094-A | Transdermal pharmaceutical composition | SYNTHELABO (FR) | 1996-06-04 | — | — | US | claimed |
| EP-0582502-A1 | Transdermal composition containing alfuzosin | SYNTHELABO (FR) | 1994-02-09 | — | — | EP | claimed |
| JP-6157315-A | — | — | None | — | — | JP | disclosed |
| EP-4561553-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF POST-TRAUMATIC STRESS SYNDROME | Kinnov Therapeutics (FR) | 2025-06-04 | — | — | EP | disclosed |
| US-20240252516-A1 | COMBINATION BPH THERAPY WITH FEXAPOTIDE TRIFLUTATE, A 5-ARI, AND AN ALPHA BLOCKER | NYMOX CORPORATION | 2024-08-01 | — | — | US | disclosed |
| WO-2024023441-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF POST-TRAUMATIC STRESS SYNDROME | Kinnov Therapeutics (FR) | 2024-02-01 | — | — | WO | disclosed |
| EP-3220942-B1 | COMPOSITIONS COMPRISING LOW DOSE DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | SERENITY PHARMACEUTICALS LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10286033-B2 | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist | SERENITY PHARMACEUTICALS, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-9925232-B2 | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor | SERENITY PHARMACEUTICALS, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| WO-1994011004-A1 | 17 SUBSTITUTED ACYL-3-CARBOXY 3,5-DIENE STEROIDALS AS 5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994011386-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0582502-A1 | Transdermal composition containing alfuzosin | SYNTHELABO (FR) | 1994-02-09 | — | — | EP | disclosed |
| EP-0582502-A1 | Transdermal composition containing alfuzosin | SYNTHELABO (FR) | 1994-02-09 | — | — | EP | disclosed |
| WO-1994000121-A1 | 17-ACYL-4-AZA-STEROID-3-ONE AS 5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000125-A1 | 17-ALKYLKETONE STEROIDS USEFUL AS 5-α-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069562-A1 | Process for the preparation of alfuzosin | QDPR, OPRD1, OPRK1 | KDM4E 716/4885HPGD 565/4885ALDH1A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.